SUSANNAH GRAY - 26 Feb 2023 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Role: Director
Signature: /s/ Brett A. Grimaud, Attorney-in-Fact
Issuer symbol: TBPH
Transactions as of: 26 Feb 2023
Net transactions value: $0
Form type: 4
Filing time: 28 Feb 2023, 19:17:32 UTC
Previous filing: 10 Jun 2022
Next filing: 04 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TBPH	Ordinary Shares	Award	$0	+10,131		$0.000000	10,131	26 Feb 2023	Direct
transaction	TBPH	Ordinary Shares	Award	$0	+1,688	+17%	$0.000000	11,819	26 Feb 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TBPH	Share Option (Right to Buy)	Award	$0	+28,000		$0.000000	28,000	26 Feb 2023	Ordinary Shares	28,000	$9.87	Direct	F1
transaction	TBPH	Share Option (Right to Buy)	Award	$0	+4,666		$0.000000	4,666	26 Feb 2023	Ordinary Shares	4,666	$9.87	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option vests monthly over 24 months of service from the date of grant.
F2	This option shall vest monthly over two months of service from the date of grant and will vest in full upon earlier of the two-month anniversary of Susannah Gray's appointment to the Board or the date of Company's 2023 annual meeting of Shareholders.